ℹ️
🇬🇧
Search
Search for publications relevant for "PI3Kδ inhibitor"
PI3Kδ inhibitor
Publication
Class
Person
Publication
Programmes
publication
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
2021 |
Faculty of Medicine in Hradec Králové
publication
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
2023 |
First Faculty of Medicine, Faculty of Medicine in Hradec Králové
publication
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
2023 |
First Faculty of Medicine
publication
Randomized, Placebo-Controlled, Phase 3 Trial of PI3Kδ Inhibitor Leniolisib for Activated PI3Kδ Syndrome
2023 |
Second Faculty of Medicine
publication
Idelalisib in the treatment of patients with follicular lymphoma
2015 |
Faculty of Medicine in Hradec Králové
publication
Interim Analysis: Open-Label Extension Study of Leniolisib for Patients with APDS
2024 |
Second Faculty of Medicine
publication
Idelalisib in the treatment of chronic lymphocytic leukaemia
2015 |
First Faculty of Medicine